Growth Hormone Secretagogues

CJC-1295

CJC-1295 with/without DAC · Modified GHRH

A long-acting GHRH analogue that extends growth hormone pulses; often stacked with ipamorelin for synergistic GH release.

Overview & Mechanism

Binds serum albumin via a drug affinity complex (DAC), extending half-life, and stimulates the GHRH receptor to increase baseline GH and IGF-1 over several days.

Research Dosage

Dose

1–2 mg/week (no DAC); 2 mg/week (DAC)

Route

Subcutaneous injection

Frequency

Once or twice weekly

Cycle

8–12 weeks

Reconstitution & Storage

Reconstitution

Reconstitute a 2 mg vial with 2 mL of bacteriostatic water (1 mg/mL).

Storage

Lyophilized: −20 °C. Reconstituted: refrigerate 2–8 °C, use within 28–30 days.

Safety & Side Effects

May cause water retention, joint discomfort, or tingling initially. DAC form has a longer half-life (weekly dosing).

Studies

CJC-1295 increases IGF-1 in healthy subjects

A single dose of CJC-1295 increased IGF-1 levels for up to 6 days in healthy adults, with a favorable safety profile.

Read study

References

Research Use Only

This information is intended for licensed researchers and educational purposes only. It does not constitute medical advice. PureLife Health products are not approved for human use by Health Canada or the FDA. Always consult a qualified medical professional and verify against current literature.